EXIQON
LIVE

Serial Number

79204234

Owner

QIAGEN GmbH

Filing Date

Oct 4, 2016

Add to watchlist:

No watchlists yet
View on USPTO

EXIQON Trademark

Serial Number: 79204234 • Registration: 5547745

EXIQON is a trademark filed by QIAGEN GmbH on October 4, 2016. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

QIAGEN GmbH

QIAGEN Straße 1
Hilden 40724 , DE

Entity Type: 99

Exiqon A/S (36 trademarks)

Bygstubben 9
2950 Vedbaek , DK

Entity Type: 03

Trademark Details

Filing Date

October 4, 2016

Registration Date

August 28, 2018

Published for Opposition

June 12, 2018

Cancellation Date

March 14, 2025

Goods & Services

Chemical, biochemical and biological products, namely, reagents and tissues and reagents for industrial and scientific purposes; diagnostic reagents, except for medical or veterinary use; biochemical reagents and products, comprising industrial chemicals, catalysts for chemical and biochemical processes and chemical assays for analysis of nucleic acid, nucleotide bases, oligo nucleotide bases, DNA and RNA, used for non-medical purposes; chemical reagents except for medical or veterinary purposes; biochemical kits comprising chemicals, catalysts for chemical and biochemical processes, chemical and biochemical assays, biochemical probes, biochemical reagents and enzymes, not for medical or veterinary purposes, for analysis of genes, nucleic acid, nucleotide bases, oligo nucleotide bases, DNA, RNA and microRNA and for detecting RNA and microRNA; biochemical probes and microarray probes for analysis of DNA, RNA, nucleotide bases, oligo nucleotide bases, nucleic acid and for detecting RNA and microRNA - not for medical and veterinary purposes

Chemical, biochemical and biological preparations, products, namely, reagents and tissues, and reagents for pharmaceutical, medical and veterinary purposes, namely, clinical medical reagents, diagnostic reagents, and assays for medical use; chemical pharmaceutical preparations, namely, for use in the detection of cancer in humans and animals and for use in oncology and for use in the prevention, treatment and cure of cancer; chemical reagents for medical and veterinary purposes; chemical preparations for therapeutic purposes for the detection of cancer in humans and animals and for the treatment, prevention and cure of cancer and for use in oncology; diagnostic preparations for medical and veterinary purposes

Research, development of chemical, biochemical and biological products, industrial analysis, validation experiments and non-business consultancy relating to chemical analyses of genes, nucleic acid, nucleotide bases, oligo nucleotide bases, DNA, RNA and microRNA; biotechnical consultancy relating to genes, nucleic acid, nucleotide bases, oligo nucleotide bases, DNA, RNA and microRNA, peptide syntheses and nucleotide syntheses; assay development, screening biomarker detection and development projects in the nature of biochemical and biological product development, sampling of biochemical and biological products, method development of analysis of genes, nucleic acid, nucleotide bases, oligo nucleotide bases, DNA, RNA and microRNA and validation projects in the nature of analysis of genes, nucleic acid, nucleotide bases, oligo nucleotide bases, DNA, RNA and microRNA, the aforesaid services for use in relation to biotechnological industry and biotechnological and biological research and development; biochemical and biological sequencing, the aforesaid services for use in relation to biotechnological industry and biotechnological and biological research and development; design and development of computer software, including cloud computing and application software for computers; scientific consultancy services relating to DNA peptide and nucleotide syntheses

Apparatus for recording, transmission and reproduction of sound or images; prerecorded magnetic data carriers featuring information about biochemical research results and biochemical products and solutions for use in database management, prerecorded recording discs featuring information about biochemical research results and biochemical products and solutions for use in database management; compact discs, featuring data for use in connection with chemical and biochemical analyses of genes, DNA, RNA, nucleic acid, nucleotide bases, oligo nucleotide bases; DVDs, featuring data for use in connection with chemical and biochemical analyses of genes, DNA, RNA, nucleic acid, nucleotide bases, oligo nucleotide bases and other digital recording media, namely, prerecorded digital video discs and prerecorded digital versatile discs featuring information about biochemical research results and biochemical products and solutions; downloadable computer software for use in database management; downloadable cloud computing software for managing virtual machines on a cloud computing platform, and application software for computers for use in database management

Filing History

TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Jun 11, 2026 INTS
INVALIDATION PROCESSED
Jun 11, 2026 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Nov 14, 2025 INTR
CANCELLED SECTION 71
Mar 14, 2025 C71T
NEW REPRESENTATIVE AT IB RECEIVED
Apr 3, 2021 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Apr 19, 2019 NREP
CHANGE OF OWNER RECEIVED FROM IB
Mar 15, 2019 CHLD
FINAL DECISION TRANSACTION PROCESSED BY IB
Jan 5, 2019 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Dec 13, 2018 FICS
FINAL DISPOSITION PROCESSED
Dec 12, 2018 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 28, 2018 FICR
REGISTERED-PRINCIPAL REGISTER
Aug 28, 2018 R.PR
PUBLISHED FOR OPPOSITION
Jun 12, 2018 PUBO
NOTIFICATION PROCESSED BY IB
Jun 8, 2018 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
May 23, 2018 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
May 23, 2018 OP2R
NOTICE OF PUBLICATION
May 23, 2018 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
May 8, 2018 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 3, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 2, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 2, 2018 TROA
NON-FINAL ACTION MAILED
Nov 16, 2017 CNRT
NON-FINAL ACTION WRITTEN
Nov 15, 2017 CNRT
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Nov 8, 2017 LIMN
LIMITATION OF GOODS RECEIVED FROM IB
Oct 27, 2017 LIMG
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 25, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 25, 2017 CRFA
ASSIGNED TO LIE
Oct 23, 2017 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 9, 2017 TROA
NEW REPRESENTATIVE AT IB RECEIVED
Jun 30, 2017 NREP
REFUSAL PROCESSED BY IB
May 13, 2017 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 21, 2017 RFCS
REFUSAL PROCESSED BY MPU
Apr 21, 2017 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 19, 2017 RFCR
NON-FINAL ACTION WRITTEN
Apr 18, 2017 CNRT
APPLICATION FILING RECEIPT MAILED
Apr 7, 2017 MAFR
ASSIGNED TO EXAMINER
Apr 3, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 3, 2017 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 30, 2017 REPR